ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,370.30
-0.71%
S&P ASX All Technology
3,878.20
-0.22%
Brent Oil
78.095
-0.31%
US Dollar vs AUD
1.59363
-0.03%
Bitcoin
102,070.52
-1.51%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Cue Biopharma Inc (CUE) Share Price

Cue Biopharma Inc

Cue Biopharma Inc (CUE)

Cue Energy Resources Limited
1.22
0.01
(0.83%)
Closed 23 January 8:00AM
Delayed by 15 minutes
1.22
0.00
(0.00%)
After Hours: 9:11AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.22
Bid
1.21
Offer
1.22
Volume
451,470
1.111 Day's Range 1.22
0.45 52 Week Range 2.93
Market Cap
77.287M
Previous Close
1.21
Open
1.19
Last Trade
22
@
1.22
Last Trade Time
Financial Volume
US$ 523,521
VWAP
1.1596
Average Volume (3m)
474,240
Shares Outstanding
63,350,327
Dividend Yield
-
PE Ratio
-1.52
Earnings Per Share (EPS)
-0.8
Revenue
5.49M
Net Profit
-50.73M

About Cue Biopharma Inc

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant ... Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.cuebiopharma.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Cue Biopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CUE. The last closing price for Cue Biopharma was US$1.21. Over the last year, Cue Biopharma shares have traded in a share price range of US$ 0.45 to US$ 2.93.

Cue Biopharma currently has 63,350,327 shares in issue. The market capitalisation of Cue Biopharma is US$76.65 million. Cue Biopharma has a price to earnings ratio (PE ratio) of -1.52.

Ask ADVFN Intelligence (AI)

CUE Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

04 January 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 January 2025
Edgar (US Regulatory)

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively...

30 November 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

30 November 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

30 November 2024
Edgar (US Regulatory)

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage...

26 November 2024
GlobeNewswire Inc.

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage...

15 November 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

15 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

15 November 2024
Edgar (US Regulatory)

Cue Biopharma Announces Strategic Organizational Transition

Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish Suri, Ph.D., president & chief scientific...

15 November 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.01-0.8130081300811.231.36351.172674181.2634774CS
40.1918.44660194171.031.750.954175921.35108909CS
12-0.54-30.68181818181.761.98910.924742401.33890498CS
260.4660.52631578950.761.98910.455745641.15816087CS
52-1.56-56.11510791372.782.930.454485361.34281416CS
156-7.39-85.83042973298.6111.230.453618412.81469039CS
260-14.22-92.098445595915.4435.50.453402157.55105323CS

CUE - Frequently Asked Questions (FAQ)

What is the current Cue Biopharma share price?
The current share price of Cue Biopharma is US$ 1.22
How many Cue Biopharma shares are in issue?
Cue Biopharma has 63,350,327 shares in issue
What is the market cap of Cue Biopharma?
The market capitalisation of Cue Biopharma is USD 76.65M
What is the 1 year trading range for Cue Biopharma share price?
Cue Biopharma has traded in the range of US$ 0.45 to US$ 2.93 during the past year
What is the PE ratio of Cue Biopharma?
The price to earnings ratio of Cue Biopharma is -1.52
What is the cash to sales ratio of Cue Biopharma?
The cash to sales ratio of Cue Biopharma is 14.07
What is the reporting currency for Cue Biopharma?
Cue Biopharma reports financial results in USD
What is the latest annual turnover for Cue Biopharma?
The latest annual turnover of Cue Biopharma is USD 5.49M
What is the latest annual profit for Cue Biopharma?
The latest annual profit of Cue Biopharma is USD -50.73M
What is the registered address of Cue Biopharma?
The registered address for Cue Biopharma is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Cue Biopharma website address?
The website address for Cue Biopharma is www.cuebiopharma.com
Which industry sector does Cue Biopharma operate in?
Cue Biopharma operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BLBXBlackBoxStocks Inc
US$ 5.53
(227.22%)
229.08M
ASSTAsset Entities Inc
US$ 1.36
(51.11%)
121.68M
STAIScanTech AI Systems Inc
US$ 2.12
(44.22%)
51.68M
JYDJayud Global Logistics Ltd
US$ 3.53
(42.91%)
1.27M
NTRBNutriband Inc
US$ 7.39
(41.84%)
3.88M
STFSStar Fashion Culture Holdings Ltd
US$ 2.62
(-80.61%)
30.25M
HEPAHepion Pharmaceuticals Inc
US$ 0.135
(-58.05%)
39.89M
STBXStarBox Group Holdings Ltd
US$ 0.6201
(-36.50%)
1.63M
WHLRLWheeler Real Estate Investment Trust Inc
US$ 93.51
(-35.73%)
1
JUNSJupiter Neurosciences Inc
US$ 3.61
(-33.39%)
6.87M
IPAImmunoPrecise Antibodies Ltd
US$ 0.6446
(30.75%)
296.43M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.3191
(33.57%)
229.11M
BLBXBlackBoxStocks Inc
US$ 5.53
(227.22%)
229.08M
NVDANVIDIA Corporation
US$ 147.07
(4.43%)
216.62M
RGTIRigetti Computing Inc
US$ 13.89
(-0.64%)
154.54M

CUE Discussion

View Posts
boston127 boston127 2 weeks ago
Send URL for the funds loading info.

I also bought today and last week, but am RED because I bought at a higher price.
👍️0
Hawkeye_tt Hawkeye_tt 2 weeks ago
You can easily see when a Fund is loading for the day.
I backed up the truck in the 50 cent dip area. That was a gift.
GL all.....be patient.

Hawk
👍️0
boston127 boston127 2 weeks ago
Today's volume was heavier than usual,

trading 1,209,308 shares, versus an average of 459,032 shares per day during the last twelve months. The On Balance Volume indicator (OBV) shows that longer term selling pressure has given way to near term accumulation by traders.
👍️0
boston127 boston127 2 weeks ago
Momentum for CUE is strongly bullish.

The 14-period Slow Stochastic Oscillator is rising, as investors pay higher prices for shares. Good day today. Got back in recently. Will continue adding all the way to $3.
👍️0
boston127 boston127 2 weeks ago
Thanks. Interesting perspective.

As long as the company is doing well, I can wait and suffer through any dips.
👍️0
Hawkeye_tt Hawkeye_tt 2 weeks ago
This could be Over $5 right now...IMO. Algos/shorts walked this down for mths.
LT looks very good IMO.

Hawk
👍️0
boston127 boston127 3 weeks ago
Great day on Friday.

Wondering if profit taking will follow suit this week.
👍️0
Hawkeye_tt Hawkeye_tt 3 weeks ago
2025 should be a very good yr. New Partnerships and more.

Hawk
👍️0
glenn1919 glenn1919 3 weeks ago
cue.........................https://stockcharts.com/h-sc/ui?s=cue&p=W&b=5&g=0&id=p86431144783
👍️0
Hawkeye_tt Hawkeye_tt 3 months ago
TY for that quick dip/Algo dump op. Took advantage big time.
GL all...

Hawk
👍️0
boston127 boston127 3 months ago
Momentum for CUE is waning,

as measured by a 14-period Slow Stochastic Oscillator. This means that investors are less aggressive in their recent purchases and may even be taking profits in positions bought at lower prices.
👍️0
boston127 boston127 4 months ago
The On Balance Volume indicator (OBV) is bullish.

The slope of the indicator is positive and suggests that buyers are presently more active than sellers.Today's volume was heavier than usual, trading 2,320,021 shares, versus an average of 389,835 shares per day during the last twelve months.
👍️0
boston127 boston127 4 months ago
Momentum for CUE is strongly bullish.

The 14-period Slow Stochastic oscillator is above 80, the level which many analysts call overbought. This means that investors have been actively purchasing shares and driving the price higher.
👍️0
boston127 boston127 4 months ago
I got in on Friday. Everything

about the company is good. Gotta love it. They did not give up much to get that $11M in financing. Will buy on dips. Bought a little more today.
👍️0
Monksdream Monksdream 4 months ago
CUE under $2
👍️0
Hawkeye_tt Hawkeye_tt 4 months ago
Look at that Wkly candle ! Vol fantastic.
LT outlook back on !

Hawk
👍️0
Triple nickle Triple nickle 4 months ago
CUE ready to win 1.02
👍️0
Hawkeye_tt Hawkeye_tt 4 months ago
Strong recovery on news....future looking good here. Buy, hold LT...
Hawk
👍️0
Monksdream Monksdream 7 months ago
CUE new 52 week low
👍️0
Hawkeye_tt Hawkeye_tt 2 years ago
CUE....this story grows quickly. Merck early investor.
Last few wks it has been breaking out.
$5 break next. More Partners want in, on top of Ono.

Hawk
👍️0
conix conix 3 years ago
CUE Insider Buy
Cue Biopharma Aaron G.L. Fletcher Director Buy 735,000 shares @ $4.76 $3,498,600.00 3/31/2022
👍️0

Your Recent History

NASDAQ
CUE
Cue Biopharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads